Annual General Meeting - Shareholders approve all proposals of the Board of Directors
|
COLTENE Holding AG
/ Key word(s): Miscellaneous
Media Release Altstätten, 21 April, 2022 After two years, today's Annual General Meeting was again held in Altstätten with shareholders in attendance as usual. The shareholders approved all proposals of the Board of Directors with a large majority and decided on a dividend of CHF 3.30 per share. 177 shareholders with voting rights were present and a total of 78.4% of the votes were represented. At the AGM, which was held in physical form, the shareholders approved the Management Report, the Annual and Consolidated Financial Statements for 2021, and the profit to be carried forward to 2022. In addition, they approved the distribution of CHF 3.30 per share from the capital contribution reserves with foreign reference. The members of the Board of Directors and the Executive Committee were discharged from liability. The shareholders confirmed all members of the Board of Directors and the Compensation Committee standing for re-election and re-elected Nick Huber as Chairman. Board members Erwin Locher and Matthew Robin announced that this will be their last term of office and that they will not be available for re-election next year. Ernst & Young AG, St. Gallen, was confirmed as auditor. Finally, the shareholders approved the Compensation Report 2021 in an advisory vote and approved the fixed compensation to the members of the Board of Directors for the period from the AGM 2022 to the AGM 2023 and to the Executive Committee for the financial year 2023 as proposed. The distribution of CHF 3.30 per share represents a yield of 2.9% based on a share price of CHF 112.40 (as of 31 December) and will be paid on 27 April 2022 (payment date). It will be paid tax-free to individuals with tax domicile in Switzerland.
About COLTENE COLTENE is an international developer, manufacturer and seller of dental consumables and small equipment in the areas of Infection Control, Dental Preservation and Efficient Treatment. COLTENE has state-of-the-art production facilities in the USA, Canada, Germany, France and Switzerland as well as own sales organizations in all major markets including Europe, North and Latin America, Japan, China and India. Dentists, DSOs, dental clinics and dental labs all around the globe trust COLTENE's high-quality products. The registered shares of COLTENE Holding AG (CLTN) are listed on SIX Swiss Exchange. Learn more about COLTENE and our products at www.coltene.com. Contact information This written statement and oral statements or other statements made, or to be made, by us contain forward-looking statements that do not relate solely to historical or current facts. These forward-looking statements are based on the current plans and expectations of our management and are subject to a number of uncertainties and risks that could significantly affect our current plans and expectations, as well as future results of operations and financial condition. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of Media Release |
| Language: | English |
| Company: | COLTENE Holding AG |
| Feldwiesenstrasse 20 | |
| 9450 Altstätten | |
| Switzerland | |
| ISIN: | CH0025343259 |
| Valor: | 2534325 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1332463 |
| End of News | EQS News Service |
|
|
1332463 21.04.2022
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.